David Armstrong
Senior Reporter at ProPublica
Senior Reporter @ProPublica [email protected] 718-710-9494 for calls, messages and Signal
Articles
-
3 weeks ago |
propublica.org | Max Blau |Margaret Coker |David Armstrong |Vernal Coleman
ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. The mother of an Arizona man who died after being unable to find mental health treatment is suing his health insurer, saying it broke the law by publishing false information that misled its customers.
-
1 month ago |
propublica.org | Margaret Coker |David Armstrong |Vernal Coleman |Eric Umansky
This article was produced for ProPublica’s Local Reporting Network in partnership with The Current. Sign up for Dispatches to get stories like this one as soon as they are published. Last summer, as political debate swirled over the future of Georgia’s experiment with Medicaid work requirements, Gov. Brian Kemp held a press conference to unveil a three-minute testimonial video featuring a mechanic who works on classic cars.
-
1 month ago |
propublica.org | Margaret Coker |David Armstrong |Vernal Coleman |Eric Umansky
This article was produced for ProPublica’s Local Reporting Network in partnership with The Current. Sign up for Dispatches to get stories like this one as soon as they are published. When the state of Georgia handed Deloitte Consulting a $10.7 million marketing contract last July to promote the nation’s only Medicaid work requirement program, the initiative was in need of serious PR.
-
1 month ago |
propublica.org | David Armstrong |Vernal Coleman |Eric Umansky |Kavitha Surana
ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. In the U.S., the price of Revlimid, a brand-name cancer drug, has been increasing for two decades. It now sells for nearly $1,000 a pill. In Europe, the price has been consistently lower — in some countries by two-thirds. I started reporting on Revlimid after I was prescribed the drug following a diagnosis of multiple myeloma, an incurable blood cancer.
-
1 month ago |
propublica.org | David Armstrong |Kavitha Surana |Lizzie Presser |Andrea Suozzo
ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. The pain jolted me awake. It was barely dawn, a misty February morning in 2023. My side felt as if I’d been stabbed. I had been dealing with pain for weeks — a bothersome ache that felt like a bad runner’s cramp. But now it was so intense I had to brace myself against the wall to stand up.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 1K
- DMs Open
- Yes
I have written many healthcare stories, but none about my own health until now. I decided to do so after learning one of my drugs costs nearly $1,000 a pill and just 25 cents to make. What I found was an incredible story of discovery and exploitation.https://t.co/PkjRpTqHj9
The momentum from dramatic improvements in cancer treatment over the past two decades is now at risk https://t.co/IVfaAqMMXk
Who wins when a major opioid manufacturer settles federal claims of reckless behavior? The lawyers ($350 million) and company executives ($95 million in bonuses). Losers? Opioid victims (about $1,000 per victim). Read the details here - https://t.co/r875qe5YCG